204 related articles for article (PubMed ID: 16981982)
1. Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-up.
Vila-Córcoles A; Ochoa-Gondar O; Ester F; Sarrá N; Ansa X; Saún N;
BMC Public Health; 2006 Sep; 6():231. PubMed ID: 16981982
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
4. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
5. Increasing pneumococcal vaccination in managed care through telephone outreach.
Winston CA; Mims AD; Leatherwood KA
Am J Manag Care; 2007 Oct; 13(10):581-8. PubMed ID: 17927463
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia.
Vila-Corcoles A; Ochoa-Gondar O; Hospital I; de Diego C; Satué E; Bladé J; Ansa X; Guzmán JA; Salsench E; Ramos F
Hum Vaccin Immunother; 2016 Nov; 12(11):2953-2958. PubMed ID: 27454779
[TBL] [Abstract][Full Text] [Related]
8. Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain.
Jiménez-García R; Ariñez-Fernandez MC; Hernández-Barrera V; Garcia-Carballo MM; de Miguel AG; Carrasco-Garrido P
J Infect; 2007 Jan; 54(1):65-74. PubMed ID: 17049991
[TBL] [Abstract][Full Text] [Related]
9. Invasive pneumococcal disease in Catalonian elderly people, 2002-2009: serotype coverage for different anti-pneumococcal vaccine formulations at the beginning of the new conjugate vaccines era.
Vila-Corcoles A; Ochoa-Gondar O; Gomez-Bertomeu F; Raga-Luria X;
Vaccine; 2011 Oct; 29(43):7430-4. PubMed ID: 21803108
[TBL] [Abstract][Full Text] [Related]
10. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥60 years-a population-based retrospective cohort study.
Kolditz M; Schmitt J; Pletz MW; Tesch F
Clin Microbiol Infect; 2018 May; 24(5):500-504. PubMed ID: 28830805
[TBL] [Abstract][Full Text] [Related]
11. [Coverage and association with clinical variables of antipneumococcal vaccination of the population over 65 years old in Tarragona-Valls].
Vila Córcoles A; Ochoa Gondar O; Ansa Echeverría X; Bladé Creixenti J; Palacios Llamazares L; Fuentes Bellido CM
Rev Esp Salud Publica; 2005; 79(6):645-54. PubMed ID: 16457056
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of community dwelling elderly not vaccinated for pneumococcus in 1998 and 2001.
Hoover DR; Sambamoorthi U; Crystal S
Prev Med; 2004 Sep; 39(3):517-27. PubMed ID: 15313091
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017.
Vila-Córcoles A; Ochoa-Gondar O; de Diego C; Satué E; Vila-Rovira A; Aragón M
Euro Surveill; 2019 Jul; 24(29):. PubMed ID: 31339099
[TBL] [Abstract][Full Text] [Related]
16. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
17. Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A; Gomez F; Raga X; de Diego C; Satue E; Salsench E;
BMC Public Health; 2012 Mar; 12():222. PubMed ID: 22436146
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
19. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
Pírez MC; Algorta G; Cedrés A; Sobrero H; Varela A; Giachetto G; Montano A
Pediatr Infect Dis J; 2011 Aug; 30(8):669-74. PubMed ID: 21407145
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
